Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Barinthus Biotherapeutics (BRNS) Receivables - Net (2020 - 2023)

Barinthus Biotherapeutics (BRNS) has disclosed Receivables - Net for 4 consecutive years, with $172000.0 as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Receivables - Net fell 99.05% year-over-year to $172000.0, compared with a TTM value of $172000.0 through Mar 2023, down 99.05%, and an annual FY2022 reading of $323000.0, up 1515.0% over the prior year.
  • Receivables - Net was $172000.0 for Q1 2023 at Barinthus Biotherapeutics, down from $323000.0 in the prior quarter.
  • Across five years, Receivables - Net topped out at $18.0 million in Q1 2022 and bottomed at $20000.0 in Q4 2021.
  • Average Receivables - Net over 4 years is $2.2 million, with a median of $172000.0 recorded in 2023.
  • The sharpest move saw Receivables - Net skyrocketed 5672.76% in 2022, then tumbled 99.05% in 2023.
  • Year by year, Receivables - Net stood at $518000.0 in 2020, then plummeted by 96.14% to $20000.0 in 2021, then skyrocketed by 1515.0% to $323000.0 in 2022, then tumbled by 46.75% to $172000.0 in 2023.
  • Business Quant data shows Receivables - Net for BRNS at $172000.0 in Q1 2023, $323000.0 in Q4 2022, and $26000.0 in Q3 2022.